Skip to main content
FBLG
NASDAQ Life Sciences

FibroBiologics' Diabetic Foot Ulcer Drug Cywc628 Enters Phase 1/2 Clinical Trial

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.42
Mkt Cap
$5.129M
52W Low
$1.03
52W High
$22.6
52W Position info
38% above low
Off High info
94% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

FBLG sits 38% above its 52-week low of $1.03.

Summary

FibroBiologics announced the release of its Cywc628 drug product, initiating a Phase 1/2 clinical trial for diabetic foot ulcers to evaluate its safety, tolerability, and efficacy. This marks a significant step in the company's pipeline development, moving a key asset into human trials. This positive product development occurs amidst recent financial challenges, including a Q1 2026 net loss of $5.0 million, a going concern warning, and the launch of a $6.15 million At-The-Market offering. For a micro-cap biotech, advancing a drug into clinical trials is a material event that could provide some positive sentiment, despite the company's precarious financial position. Traders will be watching for initial trial results and updates on the company's financial stability.

At the time of this announcement, FBLG was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $1.03 to $22.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

FBLG - Latest Insights

FBLG
Oct 08, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.13
Real-time Price: $1.04 info
Change: -$0.090 (-8%) info
Market Cap: $6.173M info
FBLG
Sep 18, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.43
Real-time Price: $1.04 info
Change: -$0.390 (-27%) info
Market Cap: $6.173M info
FBLG
Sep 17, 2026, 4:01 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $1.49
Real-time Price: $1.04 info
Change: -$0.445 (-30%) info
Market Cap: $6.173M info
FBLG
Sep 15, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.55
Real-time Price: $1.04 info
Change: -$0.5079 (-33%) info
Market Cap: $6.173M info
FBLG
Aug 11, 2026, 8:30 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $1.04 info
Change: +$0.090 (+9%) info
Market Cap: $6.173M info